{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:07:57Z","timestamp":1788890877711,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kafr El Shiekh University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinsonism is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and \u03b1-synuclein aggregation within the substantia nigra pars compacta (SNc). We investigated the potential neuroprotective effects of metformin and empagliflozin, individually and combined, in a rotenone-induced Parkinsonism in rats. Rats were assigned to control, rotenone (ROT), metformin\u2009+\u2009ROT, empagliflozin\u2009+\u2009ROT, and combined metformin+empagliflozin\u2009+\u2009ROT groups. Motor function was assessed using the open field test, static rod test, and inverted grid test. Both metformin and empagliflozin monotherapies significantly improved motor deficits, while the combination therapy demonstrated superior efficacy compared to either treatment alone (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Histopathological and immunohistochemical findings further showed that the combined therapy markedly attenuated neuronal degeneration and \u03b1-synuclein deposition relative to monotherapies (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Biochemically, metformin was more effective than empagliflozin in preserving dopamine levels, with a significant difference observed between the two treatments (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Notably, the combination therapy achieved the greatest overall improvement, significantly surpassing both the ROT group and empagliflozin (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and showing comparable effects to metformin (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05). Additionally, the combined treatment restored PI3K\/AKT signaling activity and significantly upregulated PPAR-\u03b3 expression (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001 vs. ROT). Collectively, these findings suggest that combined metformin and empagliflozin therapy exerts enhanced neuroprotective effects through modulation of protein aggregation pathways, highlighting a promising drug-repositioning strategy for Parkinsonism.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-68289-w","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:13:51Z","timestamp":1788887631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPAR\u03b3 modulation"],"prefix":"10.1038","volume":"16","author":[{"given":"Marwa M.","family":"Mona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany M.","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7246-973X","authenticated-orcid":false,"given":"Al-Shimaa A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimaa A.","family":"Abass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanad S.","family":"El-Kholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"2","key":"68289_CR1","first-page":"463","volume":"32","author":"S Rahman","year":"2023","unstructured":"Rahman, S. et al. Assessment of the relationship between non-motor features and severity of Parkinson\u2019s disease patients in Bangladesh. Mymensingh Med. J. MMJ. 32 (2), 463\u2013475 (2023).","journal-title":"Mymensingh Med. journal: MMJ"},{"issue":"1","key":"68289_CR2","first-page":"1","volume":"40","author":"HM Borg","year":"2020","unstructured":"Borg, H. M., Kabel, A. & Abdel-Kareem, M. Effect of metformin and indole-3-carbinol on a rat model of Parkinson\u2019s disease induced by 6-hydroxydopamine. Bull. Egypt. Soc. Physiol. Sci. 40 (1), 1\u201314 (2020).","journal-title":"Bull. Egypt. Soc. Physiological Sci."},{"issue":"3","key":"68289_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41380-021-01394-6","volume":"27","author":"P Lindholm","year":"2022","unstructured":"Lindholm, P. & Saarma, M. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Mol. Psychiatr. 27 (3), 1310\u20131321 (2022).","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"68289_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/etm.2023.11934","volume":"25","author":"W Yang","year":"2023","unstructured":"Yang, W. et al. Active constituents of saffron (Crocus sativus L.) and their prospects in treating neurodegenerative diseases. Exp. Therapeut. Med. 25 (5), 235 (2023).","journal-title":"Experimental Therapeutic Med."},{"key":"68289_CR5","doi-asserted-by":"publisher","first-page":"110002","DOI":"10.1016\/j.cbi.2022.110002","volume":"362","author":"TK Motawi","year":"2022","unstructured":"Motawi, T. K., Al-Kady, R. H., Abdelraouf, S. M. & Senousy, M. A. Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson\u2019s disease in rats: Targeting the GRP78\/PERK\/eIF2\u03b1\/CHOP pathway and miR-211-5p. Chemico-Biol. Interact. 362, 110002 (2022).","journal-title":"Chemico-Biol. Interact."},{"key":"68289_CR6","doi-asserted-by":"publisher","first-page":"121258","DOI":"10.1016\/j.lfs.2022.121258","volume":"312","author":"HH Mousa","year":"2023","unstructured":"Mousa, H. H., Sharawy, M. H. & Nader, M. A. Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: Role of BDNF, CREB and Npas4. Life Sci. 312, 121258 (2023).","journal-title":"Life Sci."},{"issue":"4","key":"68289_CR7","doi-asserted-by":"publisher","first-page":"e202012095","DOI":"10.1083\/jcb.202012095","volume":"220","author":"N Panicker","year":"2021","unstructured":"Panicker, N., Ge, P., Dawson, V. L. & Dawson, T. M. The cell biology of Parkinson\u2019s disease. J. Cell Biol. 220 (4), e202012095 (2021).","journal-title":"J. Cell Biol."},{"issue":"6","key":"68289_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jsps.2022.03.005","volume":"30","author":"S Ahmed","year":"2022","unstructured":"Ahmed, S., El-Sayed, M. M., Kandeil, M. A. & Khalaf, M. M. Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of \u03b1-synuclein and Parkin levels in rotenone-induced Parkinson\u2019s disease in rats. Saudi Pharm. J. 30 (6), 863\u2013873 (2022).","journal-title":"Saudi Pharm. J."},{"issue":"6","key":"68289_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms17060904","volume":"17","author":"S Sarkar","year":"2016","unstructured":"Sarkar, S., Raymick, J. & Imam, S. Neuroprotective and therapeutic strategies against Parkinson\u2019s disease: recent perspectives. Int. J. Mol. Sci. 17 (6), 904 (2016).","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"68289_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","volume":"33","author":"JE Frampton","year":"2019","unstructured":"Frampton, J. E. Rotigotine transdermal patch: a review in Parkinson\u2019s disease. CNS Drugs 33 (7), 707\u2013718 (2019).","journal-title":"CNS drugs"},{"key":"68289_CR11","doi-asserted-by":"crossref","unstructured":"Bette, S., Shpiner, D. S., Singer, C. & Moore, H. Safinamide in the management of patients with Parkinson\u2019s disease not stabilized on levodopa: a review of the current clinical evidence. Therapeutics and clinical risk management. 1737\u20131745. (2018).","DOI":"10.2147\/TCRM.S139545"},{"key":"68289_CR12","unstructured":"Patel, B. & Malaty, I. Parkinson disease treatment advances. Pract. Neurol. (2022)."},{"issue":"4","key":"68289_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/NDT.S2006","volume":"4","author":"J Jankovic","year":"2008","unstructured":"Jankovic, J. & Aguilar, L. G. Current approaches to the treatment of Parkinson\u2019s disease. Neuropsychiatr. Dis. Treat. 4 (4), 743\u2013757 (2008).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"68289_CR14","doi-asserted-by":"crossref","unstructured":"Peng, Y. et al. Relationship between Parkinson\u2019s disease and diabetes mellitus: Evidence from the bench to bedside. Parkinsonism Relat. Disord. 108109. (2025).","DOI":"10.1016\/j.parkreldis.2025.108109"},{"issue":"8","key":"68289_CR15","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.4103\/1673-5374.332122","volume":"17","author":"CM Labandeira","year":"2022","unstructured":"Labandeira, C. M. et al. Parkinson\u2019s disease and diabetes mellitus: common mechanisms and treatment repurposing. Neural Regenerat. Res. 17 (8), 1652\u20131658 (2022).","journal-title":"Neural regeneration Res."},{"key":"68289_CR16","doi-asserted-by":"crossref","unstructured":"Al Khzem, A. H. & Wali, S. M. Drug repurposing as an effective drug discovery strategy: A critical review. Drug. Des. Devel. Ther. 12019\u201312034. (2025).","DOI":"10.2147\/DDDT.S576701"},{"key":"68289_CR17","doi-asserted-by":"publisher","first-page":"106062","DOI":"10.1016\/j.phrs.2022.106062","volume":"176","author":"MR Rizzo","year":"2022","unstructured":"Rizzo, M. R. et al. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacol. Res. 176, 106062 (2022).","journal-title":"Pharmacol. Res."},{"key":"68289_CR18","first-page":"53","volume":"22","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T. & Sahebkar, A. Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art. EXCLI J. 22, 53 (2023).","journal-title":"EXCLI J."},{"key":"68289_CR19","doi-asserted-by":"crossref","unstructured":"Dutta, S. et al. Metformin: a review of potential mechanism and therapeutic utility beyond diabetes. Drug design, development and therapy. 1907-32. (2023).","DOI":"10.2147\/DDDT.S409373"},{"issue":"4","key":"68289_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s11010-023-04771-7","volume":"479","author":"M Alrouji","year":"2024","unstructured":"Alrouji, M. et al. Metformin role in Parkinson\u2019s disease: a double-sword effect. Mol. Cell. Biochem. 479 (4), 975\u2013991 (2024).","journal-title":"Mol. Cell. Biochem."},{"issue":"51","key":"68289_CR21","doi-asserted-by":"publisher","first-page":"42026","DOI":"10.1074\/jbc.M508628200","volume":"280","author":"A Panov","year":"2005","unstructured":"Panov, A. et al. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem. 280 (51), 42026\u201342035 (2005).","journal-title":"J. Biol. Chem."},{"key":"68289_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.neuroscience.2012.06.021","volume":"220","author":"MS Angeline","year":"2012","unstructured":"Angeline, M. S., Chaterjee, P., Anand, K., Ambasta, R. & Kumar, P. Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat. Neuroscience 220, 291\u2013301 (2012).","journal-title":"Neuroscience"},{"key":"68289_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuro.2023.03.002","volume":"96","author":"I Ishola","year":"2023","unstructured":"Ishola, I., Awogbindin, I., Olubodun-Obadun, T., Olajiga, A. & Adeyemi, O. Vinpocetine prevents rotenone-induced Parkinson disease motor and non-motor symptoms through attenuation of oxidative stress, neuroinflammation and \u03b1-synuclein expressions in rats. Neurotoxicology 96, 37\u201352 (2023).","journal-title":"Neurotoxicology"},{"key":"68289_CR24","doi-asserted-by":"crossref","unstructured":"Kang, H. Sample size determination and power analysis using the G* Power software. J. Educ. Eval. Health Profess. 18. (2021).","DOI":"10.3352\/jeehp.2021.18.17"},{"issue":"3","key":"68289_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2478\/intox-2013-0020","volume":"6","author":"N Sestakova","year":"2013","unstructured":"Sestakova, N., Puzserova, A., Kluknavsky, M. & Bernatova, I. Determination of motor activity and anxiety-related behaviour in rodents: methodological aspects and role of nitric oxide. Interdiscip. Toxicol. 6 (3), 126 (2013).","journal-title":"Interdisciplinary Toxicol."},{"key":"68289_CR26","doi-asserted-by":"crossref","unstructured":"Deacon, R. M. Measuring motor coordination in mice. J. Visual. Exp.: JoVE (75), 2609. (2013).","DOI":"10.3791\/2609"},{"key":"68289_CR27","doi-asserted-by":"crossref","unstructured":"Mann, A. & Chesselet, M-F. Techniques for motor assessment in rodents. 139\u2013157 (Elsevier, 2015).","DOI":"10.1016\/B978-0-12-405195-9.00008-1"},{"issue":"1","key":"68289_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12917-017-0982-y","volume":"13","author":"KK Zatroch","year":"2016","unstructured":"Zatroch, K. K., Knight, C. G., Reimer, J. N. & Pang, D. S. Refinement of intraperitoneal injection of sodium pentobarbital for euthanasia in laboratory rats (Rattus norvegicus). BMC Vet. Res. 13 (1), 60 (2016).","journal-title":"BMC Vet. Res."},{"key":"68289_CR29","unstructured":"Kiernan, J. Histological and histochemical methods (Scion publishing ltd, 2015)."},{"key":"68289_CR30","unstructured":"Suvarna, S. K., Layton, C. & Bancroft, J. D. Theory and practice of histological techniqueseighth. Vol. 8, 126\u2013179 (Elsevier Health Sci, 2019)."},{"issue":"3","key":"68289_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00401-008-0409-8","volume":"116","author":"TG Beach","year":"2008","unstructured":"Beach, T. G. et al. Evaluation of \u03b1-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 116 (3), 277\u2013288 (2008).","journal-title":"Acta Neuropathol."},{"key":"68289_CR32","doi-asserted-by":"crossref","unstructured":"Fayyad, E. et al. The effect of intermittent fasting on salivary inflammatory cytokines and dopamine levels. Eur. J. Dentistry 17. (2025).","DOI":"10.1055\/s-0045-1802345"},{"key":"68289_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"B Mm","year":"1976","unstructured":"Mm, B. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248\u2013254 (1976).","journal-title":"Anal. Biochem."},{"issue":"9","key":"68289_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/1947-2714.100998","volume":"4","author":"T Mahmood","year":"2012","unstructured":"Mahmood, T. & Yang, P-C. Western blot: technique, theory, and trouble shooting. North. Am. J. Med. Sci. 4 (9), 429 (2012).","journal-title":"North. Am. J. Med. Sci."},{"key":"68289_CR35","unstructured":"Sambrook, J. & Russell, D. Molecular Cloning: A Laborotory Manual, Vol. 2. (2001)."},{"issue":"4","key":"68289_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2009\u2013 \u2206\u2206CT method. Methods 25 (4), 402\u2013408 (2001).","journal-title":"methods"},{"issue":"1","key":"68289_CR37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3892\/mmr.2014.2686","volume":"11","author":"T Yogarajah","year":"2015","unstructured":"Yogarajah, T., Bee, Y-T-G., Noordin, R. & Yin, K. B. Increased peroxisome proliferator\u2013activated receptor \u03b3 expression levels in visceral adipose tissue, and serum CCL2 and interleukin-6 levels during visceral adipose tissue accumulation. Mol. Med. Rep. 11 (1), 515\u2013520 (2015).","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"68289_CR38","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10787-023-01384-w","volume":"32","author":"NN Mohammed","year":"2024","unstructured":"Mohammed, N. N., Tadros, M. G. & George, M. Y. Empagliflozin repurposing in Parkinson\u2019s disease; modulation of oxidative stress, neuroinflammation, AMPK\/SIRT-1\/PGC-1\u03b1, and wnt\/\u03b2-catenin pathways: NN Mohammed et al. Inflammopharmacology 32 (1), 777\u2013794 (2024).","journal-title":"Inflammopharmacology"},{"issue":"14","key":"68289_CR39","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/cells14141064","volume":"14","author":"S Reed","year":"2025","unstructured":"Reed, S., Taka, E., Darling-Reed, S. & Soliman, K. F. Neuroprotective effects of metformin through the modulation of neuroinflammation and oxidative stress. Cells 14 (14), 1064 (2025).","journal-title":"Cells"},{"issue":"5","key":"68289_CR40","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1021\/acs.chemrestox.0c00522","volume":"34","author":"J Innos","year":"2021","unstructured":"Innos, J. & Hickey, M. A. Using rotenone to model Parkinson\u2019s disease in mice: a review of the role of pharmacokinetics. Chem. Res. Toxicol. 34 (5), 1223\u20131239 (2021).","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"68289_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep45465","volume":"7","author":"S Heinz","year":"2017","unstructured":"Heinz, S. et al. Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation. Sci. Rep. 7 (1), 1\u201313 (2017).","journal-title":"Sci. Rep."},{"issue":"3","key":"68289_CR42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/ijms17030327","volume":"17","author":"HMA Zeeshan","year":"2016","unstructured":"Zeeshan, H. M. A., Lee, G. H., Kim, H-R. & Chae, H-J. Endoplasmic reticulum stress and associated ROS. Int. J. Mol. Sci. 17 (3), 327 (2016).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"68289_CR43","doi-asserted-by":"publisher","first-page":"44041","DOI":"10.1038\/srep44041","volume":"7","author":"DC Rodriguez Camargo","year":"2017","unstructured":"Rodriguez Camargo, D. C. et al. The redox environment triggers conformational changes and aggregation of hIAPP in Type II diabetes. Sci. Rep. 7 (1), 44041 (2017).","journal-title":"Sci. Rep."},{"issue":"4","key":"68289_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/ph18040486","volume":"18","author":"W Kruczkowska","year":"2025","unstructured":"Kruczkowska, W. et al. Overview of metformin and neurodegeneration: a comprehensive review. Pharmaceuticals 18 (4), 486 (2025).","journal-title":"Pharmaceuticals"},{"issue":"1","key":"68289_CR45","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1124\/jpet.124.002152","volume":"392","author":"S Sharma","year":"2025","unstructured":"Sharma, S. et al. Evaluation of systemic and brain pharmacokinetic parameters for repurposing metformin using intravenous bolus administration. J. Pharmacol. Exp. Ther. 392 (1), 100013 (2025).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"68289_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen, A. J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin. Pharmacokinet. 53 (3), 213\u2013225 (2014).","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"68289_CR47","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.endoen.2016.11.001","volume":"63","author":"I Romera","year":"2016","unstructured":"Romera, I. et al. Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Endocrinolog\u00eda y Nutrici\u00f3n (English Edition). 63 (10), 519\u2013526 (2016).","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n (English Edition)"},{"issue":"18","key":"68289_CR48","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1080\/14656566.2016.1258062","volume":"17","author":"J Hu","year":"2016","unstructured":"Hu, J., Zou, P., Zhang, S., Zhou, M. & Tan, X. Empagliflozin\/metformin fixed-dose combination: a review in patients with type 2 diabetes. Expert Opin. Pharmacother. 17 (18), 2471\u20132477 (2016).","journal-title":"Expert Opin. Pharmacother."},{"key":"68289_CR49","doi-asserted-by":"crossref","unstructured":"Wald, C. & Wu, C. Of mice and women: the bias in animal models (American Association for the Advancement of Science, 2010).","DOI":"10.1126\/science.327.5973.1571"},{"key":"68289_CR50","doi-asserted-by":"crossref","unstructured":"Salem, E. A. et al. Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats. Naunyn. Schmiedebergs Arch. Pharmacol. 1\u201313. (2025).","DOI":"10.1007\/s00210-025-03920-7"},{"key":"68289_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbr.2015.04.018","volume":"290","author":"S Ikemoto","year":"2015","unstructured":"Ikemoto, S., Yang, C. & Tan, A. Basal ganglia circuit loops, dopamine and motivation: A review and enquiry. Behav. Brain. Res. 290, 17\u201331 (2015).","journal-title":"Behav. Brain. Res."},{"key":"68289_CR52","doi-asserted-by":"publisher","first-page":"123289","DOI":"10.3389\/fnana.2014.00155","volume":"8","author":"J Blesa","year":"2014","unstructured":"Blesa, J. & Przedborski, S. Parkinson\u2019s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat. 8, 123289 (2014).","journal-title":"Front Neuroanat."},{"issue":"1","key":"68289_CR53","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s42003-024-06195-5","volume":"7","author":"B Santos PCRd, Heimler","year":"2024","unstructured":"Santos PCRd, Heimler, B., Koren, O., Flash, T. & Plotnik, M. Dopamine improves defective cortical and muscular connectivity during bilateral control of gait in Parkinson\u2019s disease. Commun. Biology. 7 (1), 495 (2024).","journal-title":"Commun. Biology"},{"issue":"2","key":"68289_CR54","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awaf462","volume":"149","author":"J Zu","year":"2026","unstructured":"Zu, J. et al. Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer\u2019s disease model. Brain 149 (2), 668\u2013679 (2026).","journal-title":"Brain"},{"issue":"11","key":"68289_CR55","doi-asserted-by":"publisher","first-page":"15108","DOI":"10.1007\/s12035-025-05113-y","volume":"62","author":"R AlRuwaili","year":"2025","unstructured":"AlRuwaili, R. et al. Targeting of the PI3 K\/AKT\/GSK3\u03b2 pathway in Parkinson\u2019s disease: A therapeutic blueprint. Mol. Neurobiol. 62 (11), 15108\u201315131 (2025).","journal-title":"Mol. Neurobiol."},{"key":"68289_CR56","doi-asserted-by":"crossref","unstructured":"AlRuwaili, R. et al. Targeting of the PI3 K\/AKT\/GSK3\u03b2 pathway in Parkinson\u2019s disease: A therapeutic blueprint. Mol. Neurobiol. 1\u201324. (2025).","DOI":"10.1007\/s12035-025-05113-y"},{"issue":"2","key":"68289_CR57","doi-asserted-by":"publisher","first-page":"83","DOI":"10.33696\/Signaling.6.136","volume":"6","author":"AP Yaran","year":"2025","unstructured":"Yaran, A. P., Balali, R. & Gharibzadeh, S. Astrocyte and microglial disparities in PI3K\/AKT signaling: Implications for Parkinson\u2019s disease inflammation. J. Cell. Signal. 6 (2), 83\u201391 (2025).","journal-title":"J. Cell. Signal."},{"issue":"7","key":"68289_CR58","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2174\/1389450111314070004","volume":"14","author":"AR Carta","year":"2013","unstructured":"Carta, A. R. PPAR-\u03b3: therapeutic prospects in Parkinson\u2019s disease. Curr. Drug Targets. 14 (7), 743\u2013751 (2013).","journal-title":"Curr. Drug Targets"},{"key":"68289_CR59","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.bbr.2014.08.014","volume":"274","author":"JK Barbiero","year":"2014","unstructured":"Barbiero, J. K. et al. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1, 2, 3, 6-tetrahyropyridine. Behav. Brain. Res. 274, 390\u2013399 (2014).","journal-title":"Behav. Brain. Res."},{"key":"68289_CR60","doi-asserted-by":"publisher","first-page":"120480","DOI":"10.1016\/j.lfs.2022.120480","volume":"297","author":"NOA Rasheed","year":"2022","unstructured":"Rasheed, N. O. A. & Ibrahim, W. W. Telmisartan neuroprotective effects in 3-nitropropionic acid Huntington\u2019s disease model in rats: Cross talk between PPAR-\u03b3 and PI3K\/Akt\/GSK-3\u03b2 pathway. Life Sci. 297, 120480 (2022).","journal-title":"Life Sci."},{"key":"68289_CR61","doi-asserted-by":"publisher","first-page":"105120","DOI":"10.1016\/j.neuint.2021.105120","volume":"148","author":"N Katila","year":"2021","unstructured":"Katila, N., Bhurtel, S., Park, P-H. & Choi, D-Y. Metformin attenuates rotenone-induced oxidative stress and mitochondrial damage via the AKT\/Nrf2 pathway. Neurochem. Int. 148, 105120 (2021).","journal-title":"Neurochem. Int."},{"issue":"1","key":"68289_CR62","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12974-024-03072-0","volume":"21","author":"M Wang","year":"2024","unstructured":"Wang, M. et al. Metformin normalizes mitochondrial function to delay astrocyte senescence in a mouse model of Parkinson\u2019s disease through Mfn2-cGAS signaling. J. Neuroinflamm. 21 (1), 81 (2024).","journal-title":"J. Neuroinflamm."},{"key":"68289_CR63","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fncel.2018.00440","volume":"12","author":"K Tayara","year":"2018","unstructured":"Tayara, K. et al. Divergent effects of metformin on an inflammatory model of Parkinson\u2019s disease. Front. Cell. Neurosci. 12, 440 (2018).","journal-title":"Front. Cell. Neurosci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68289-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68289-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68289-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:29:53Z","timestamp":1788888593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-68289-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68289"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-68289-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Kafrelsheikh University, Egypt (Approval No. KFS-IACUC\/150\/2023) and conducted in accordance with the Guide for the Care and Use of Laboratory Animals (U.S. National Institutes of Health, 1986).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28103"}}